300 Participants Needed

ORMD-0801 for Diabetes

MK
MS
Overseen ByMeir S. Silver, Ph.D.
Age: 18+
Sex: Any
Trial Phase: Phase 3
Sponsor: Oramed, Ltd.
Must be taking: Glucose-lowering agents
Pivotal Trial (Near Approval)This treatment is in the last trial phase before FDA approval
Prior Safety DataThis treatment has passed at least one previous human trial

Trial Summary

Will I have to stop taking my current medications?

The trial does not require you to stop taking your current glucose-lowering medications if you are on a stable dose of up to three specific types. However, if you are using injected insulin or certain other medications, you may need to stop those before joining the trial.

What data supports the effectiveness of the drug ORMD-0801 for diabetes?

The research highlights that combining different oral antidiabetic drugs can improve blood sugar control in people with type 2 diabetes, suggesting that ORMD-0801, as an oral treatment, might also help in managing diabetes effectively.12345

What makes the drug ORMD-0801 unique for treating type 2 diabetes?

ORMD-0801 is unique because it is an oral form of insulin, which is different from the traditional insulin injections used for type 2 diabetes. This oral administration could make it easier and more convenient for patients to manage their condition.678910

What is the purpose of this trial?

ORA-013-3 is a randomized, controlled study to test the efficacy and safety of an oral capsule of ORMD-0801 at several doses in patients with Type 2 Diabetes Mellitus (T2DM) who have not responded well to other glucose-lowering medications. A total of three hundred subjects will be enrolled in this study and will be required to complete this thirty-four-week clinical trial.

Research Team

MK

Miriam Kidron, Ph.D.

Principal Investigator

Oramed, Ltd.

Eligibility Criteria

This trial is for people with Type 2 Diabetes Mellitus who haven't had much success with other glucose-lowering meds. They'll be part of a study lasting about 34 weeks.

Inclusion Criteria

I have been on a stable dose of a diabetes medication for at least 3 months.
Body mass index (BMI) of ≤ 28 kg/m2 at Screening and stable weight, with no more than 5 kg gain or loss in the 3 months prior to Screening
My kidney function is good, with an eGFR of 30 ml/min or higher.
See 3 more

Exclusion Criteria

A history of > 2 episodes of severe hypoglycemia within 6 months prior to Screening
A history of hypoglycemic unawareness
My kidney function is low, with an eGFR under 30 mL/min.
See 19 more

Timeline

Screening

Participants are screened for eligibility to participate in the trial

4 weeks
3 visits (in-person)

Treatment

Participants receive double-blind treatment with ORMD-0801 or placebo for 26 weeks

26 weeks
6 visits (in-person)

Follow-up

Participants are monitored for safety and effectiveness after treatment

4 weeks
1 visit (in-person)

Treatment Details

Interventions

  • ORMD-0801
Trial Overview The study tests ORMD-0801, an oral capsule for diabetes, at two different doses (8 mg and 16 mg) compared to a placebo to see how effective and safe it is.
Participant Groups
4Treatment groups
Active Control
Placebo Group
Group I: ORMD-0801 8 mg once-daily at night - QDActive Control2 Interventions
Double-Dummy; the subject receives both experimental drug and placebo. 1 x 8 mg capsule between 8 PM to 12 Midnight and no sooner than 1 hour after dinner and 2 placebo capsules (1 in the morning and 1 at night).
Group II: ORMD-0801 8 mg twice daily - BIDActive Control2 Interventions
Double-Dummy; the subject receives both experimental drug and placebo. 1 x 8 mg capsule each morning approximately 45 minutes (±15 minutes) prior to breakfast and 1 x 8 mg capsule each night prior to bedtime (between 8 PM to 12 Midnight and no sooner than 1 hour after dinner) and 1 placebo capsule at night.
Group III: ORMD-0801 16 mg once-daily at night - QDActive Control2 Interventions
Double-Dummy; the subject receives both experimental drug and placebo. 2 x 8 mg capsules between 8 PM to 12 Midnight and no sooner than 1 hour after dinner and 1 placebo capsule in the morning.
Group IV: PlaceboPlacebo Group1 Intervention
The subject receives 3 placebo capsules.

Find a Clinic Near You

Who Is Running the Clinical Trial?

Oramed, Ltd.

Lead Sponsor

Trials
15
Recruited
2,800+

InClin, Inc.

Collaborator

Trials
3
Recruited
620+

Findings from Research

In a study of 69 patients with poorly controlled type 2 diabetes, improved control was significantly associated with better understanding of diabetes, adherence to meal plans, and regular glucose monitoring, highlighting the importance of self-care behaviors.
Interestingly, increased use of medications was inversely related to achieving better control, suggesting that patient education and lifestyle changes may be more effective than simply intensifying medication regimens.
Factors that influence improvement for patients with poorly controlled type 2 diabetes.Hartz, A., Kent, S., James, P., et al.[2022]
In a study of 4627 patients with type 2 diabetes, those with moderate or poor glycemic control were significantly more likely to change their oral antidiabetic treatment patterns, such as switching or augmenting therapy, compared to those with good control.
Men generally had worse glycemic control at the start of treatment, and younger patients were more likely to modify their therapy, indicating that initial control levels and demographics play a crucial role in treatment adjustments.
Glycemic control and the first use of oral antidiabetic agents among patients with type 2 diabetes mellitus.Mitchell, BD., Eby, EL., Lage, MJ.[2013]
In a study of type 2 diabetes patients with poor glycemic control despite insulin therapy, adding tofogliflozin significantly improved HbA1c levels, reducing them by -1.0% compared to a slight decrease in the insulin-only group.
Tofogliflozin not only helped lower HbA1c but also reduced the total daily insulin dose and weight in patients, indicating it may be a safe and effective add-on therapy for better diabetes management.
Comparison of Combined Tofogliflozin and Glargine, Tofogliflozin Added to Insulin, and Insulin Dose-Increase Therapy in Uncontrolled Type 2 Diabetes.Suzuki, K., Mitsuma, Y., Sato, T., et al.[2022]

References

Treatment of type 2 diabetes mellitus with orally administered agents: advances in combination therapy. [2021]
Factors that influence improvement for patients with poorly controlled type 2 diabetes. [2022]
Effects of age, gender, and body mass index on efficacy and hypoglycaemia outcomes across treat-to-target trials with insulin glargine 100 U/mL added to oral antidiabetes agents in type 2 diabetes. [2018]
Glycemic control and the first use of oral antidiabetic agents among patients with type 2 diabetes mellitus. [2013]
Comparison of Combined Tofogliflozin and Glargine, Tofogliflozin Added to Insulin, and Insulin Dose-Increase Therapy in Uncontrolled Type 2 Diabetes. [2022]
Oral insulin (ORMD-0801) in type 2 diabetes mellitus: A dose-finding 12-week randomized placebo-controlled study. [2023]
Efficacy and safety of 28-day treatment with oral insulin (ORMD-0801) in patients with type 2 diabetes: A randomized, placebo-controlled trial. [2022]
Different modes of action of the imidazoline compound RX871024 in pancreatic beta-cells. Blocking of K+ channels, mobilization of Ca2+ from endoplasmic reticulum, and interaction with exocytotic machinery. [2019]
Diazoxide treatment at onset preserves residual insulin secretion in adults with autoimmune diabetes. [2019]
10.United Statespubmed.ncbi.nlm.nih.gov
Insulinotropic activity of the imidazoline derivative RX871024 in the diabetic GK rat. [2018]
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top
Terms of Service·Privacy Policy·Cookies·Security